Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10967519 | 0.77 | HTT (0.47) | KDM4ETDP1L3MBTL1POLBAPEX1 | |
| SCHEMBL890409 | 0.73 | RXFP1 (0.56) | KDM4ETDP1L3MBTL1POLBAPEX1 | |
| SCHEMBL3152080 | 0.71 | PKM (0.56) | KDM4ETDP1POLBALDH1A1GRIN2A | |
| SCHEMBL890532 | 0.67 | GRIN1 (0.49) | KDM4ETDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL10966083 | 0.67 | KDM4E (0.62) | KDM4ETDP1POLBALDH1A1GRIN2A | |
| SCHEMBL23726394 | 0.67 | RXFP1 (0.56) | KDM4ETDP1L3MBTL1POLBALDH1A1 | |
| SCHEMBL890385 | 0.66 | PKM (0.56) | KDM4EALDH1A1GRIN2AGRIN1SMN1; SMN2 | |
| SCHEMBL29232190 | 0.66 | KDM4E (0.49) | KDM4ETDP1L3MBTL1POLBAPEX1 | |
| SCHEMBL17657908 | 0.64 | GRIN1 (0.48) | POLBHTTGRIN2AGRIN1GRIA2 | |
| SCHEMBL23725727 | 0.64 | KDM4E (0.43) | KDM4ETDP1L3MBTL1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531696-B | Pyridopyrimidinones as NMDA receptor modulators and their use | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3283487-B1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-3283487-A1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166078-A1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166078-A1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | PDXK, XDH, PNPO | KDM4E 1193/4885TDP1 564/4885L3MBTL1 4167/4885 |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | PDXK, XDH, PNPO | KDM4E 1193/4885TDP1 564/4885L3MBTL1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.